Vertex Pharmaceuticals will not advance clinical trials of a treatment for Type 1 diabetes after efficacy data failed to support further clinical advancement.

Zimislecel, Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the ...

Vertex' therapy takes the form of stem cell-derived human pancreatic islet cells, which secrete insulin in the body in response to rising blood glucose. The aim is to replace the pancreatic tissue ...

Vertex Pharmaceuticals is marching beyond its cystic fibrosis stronghold with bold steps into pain management and genetic ...

Jim Cramer recently fired up CNBC’s Squawk on the Street with concerns over America’s global tariff woes, calling them ...